Introduction
Central giant cell lesions (CGCLs) are rare intraosseous lesions that occur almost exclusively in the jaws and are more common in adolescents and young adults (Jundt 2005) . Microscopically, CGCL is characterized by the presence of multinucleated giant cells (MGCs) in a cellular background composed of mononucleated stromal cells (MSCs) with ovoid or spindle-shaped nuclei, which are fibroblastic in origin (Jundt 2005; de Lange and Van den Akker 2005; Kruse-Losler et al. 2006) . The giant cells themselves may vary in size, shape, and number, probably representing osteoclasts or macrophages in origin (Regezi 2002; Jundt 2005; de Lange and Van den Akker 2005; Kruse-Losler et al. 2006) . Although little is know about pathogenesis of CGCLs, some studies have shown that in the MSCs component are the proliferative cells in CGCLs (O'Malley et al. 1997; Liu et al. 2003) .
The CGCL was classified in 2005 by the World Health Organization as an idiopathic benign lesion with a variable clinical behavior ranging from a slowly growing, asymptomatic radiolucent lesion to an aggressive process associated with pain, root resorption, cortical bone destruction, and a tendency to recur after treatment (Chuong et al. 1986; Jundt 2005 ; de Lange and Van den Akker 2005; Kruse-Losler et al. 2006) . The pathogenesis of CGCL is not completely understood. There is not even agreement as to whether CGCL is a neoplasm or a reactive process (Souza et al. 1999 (Souza et al. , 2000 Kauzman et al. 2004; Nogueira et al. 2010; Nogueira et al. 2012) . Some authors regard CGCLs as lesions related to giant cell tumors (GCTs) of the bones, representing different ends of a clinical-pathological spectrum of the same diseases process (Auclair et al. 1988; Kauzman et al. 2004 ).
An imbalance in cell proliferation control is an important characteristic of aggressive lesions, in which molecules involved in the G1/S checkpoint are frequently altered (Malumbres and Barbacid 2001) . The late G1 cell cycle checkpoint is controlled by a complex of proteins that include p16
INK4a
, cyclin D1, cyclin-dependent kinases (CDKs) 4/6, and retinoblastoma protein (pRb) (Fang et al. 1998; Diehl 2002) . These proteins are components of the pRb cell cycle control pathway; cyclin D1 stimulates the phosphorylation of pRb by association with CDKs, and p16
INK4a binds to CDK4/6, blocking their association with D-type cyclins (Fig. 1) . Thus, the loss of p16
INK4a expression or overexpression of cyclin D1 cause pRb pathway dysfunction and stimulate cell proliferation (Serrano et al. 1993; Mittnacht 1998) . While the three D-type cyclins are almost indistinguishable biochemically, only cyclin D1 is frequently overexpressed in cancers. The CCND1 gene is a proto-oncogene located on chromosome 11q13 and encodes cyclin D1, and the amplification of this gene is a common mechanism that leads to aberrant overexpression of cyclin D1 (Diehl 2002) . Only one study (Kauzman et al. 2004 ) has analyzed the amplification of the CCND1 gene in CGCLs, and the expression of p16
INK4a has never been studied in CGCLs. Gathering more information regarding the genetic events involved in CGCL is an important task in understanding this lesion. Due to the role of cyclin D1 and p16
INK4a in pRb pathway, and considering that these molecules are frequently involved in tumorigenesis, the purpose of this study was to analyze CCND1 gene amplification and the expression of p16
INK4a in CGCLs of the jaws.
Materials and methods
For this study, formalin-fixed paraffin-embedded blocks of 27 consecutive cases of primary CGCLs from patients treated at Memorial Batista Hospital were retrieved from the archives of the Department of Oral and Maxillofacial Pathology, Fortaleza University, Fortaleza, Brazil. Samples were excluded based on associated diagnoses (such as cherubism or hyperparathyroidism, or Brown's tumor), insufficient clinical data to classify the behavior of the lesions as aggressive or non-aggressive, or inadequate specimen for molecular or biochemical analysis. Based on clinic and radiographic data, all cases were classified according to the criteria established by Chuong et al. (1986) (Table 1) . Fig. 1 The pRb pathway. Growth factors lead to the accumulation of cyclin D1 that interacts with CDK4. The complex cyclin d1/CDK4 phosphorylates the pRb, leading to release of the E2F complex, which directs the cell to pass through the restriction point, inducing the transcription of genes of phase S. The p16
INK4a protein, a protein of the INK4 family, binds to CDK4 and can interferes with cyclin-CDK interaction, thus inhibiting the phosphorylation of pRb, and restricting the passage of G1-S Chromogenic in situ hybridization (CISH) for CCND1 gene amplification CCND1 gene amplification was performed as previously described (Reis-Filho et al. 2006 ) using the ready-to-use digoxigenin-labeled SpoT-Light Cyclin D1 amplification probe (Zymed, South San Francisco, CA, USA). Heat pretreatment of deparaffinized sections consisted of incubation for 15 min at 98°C in CISH pretreatment buffer (SPOT-light tissue pretreatment kit, Zymed) and digestion with pepsin for 7 min at room temperature according to the manufacturer's instructions. An appropriate CCND1 geneamplified breast tumor control was included.
CISH analysis
The CISH results were evaluated by optical microscopy at high magnification (4009). Only unequivocal signals were counted. Morphologically unequivocal cells were assessed for the presence of the gene probe signals. Amplification was defined as[5 signals per nucleus in more than 50 % of lesion cells or as the presence of large gene copy clusters. High-level gene amplification was defined as more than 10 discrete copies per nucleus or as large gene copy clusters (observed as confluent masses containing more than 10 signals) in more than 50 % of the nuclei evaluated. Lowlevel amplification was defined as 5-6 copies per nucleus in more than 50 % of the cells. Moderate-level amplification was defined as 7-10 copies per nucleus in more than 50 % of the cells. Unaltered gene copy number was defined as 1-5 copies per nucleus.
Immunohistochemistry
Immunostaining was performed according to a previously described protocol (Faria et al. 2007 ). For antigen retrieval, deparaffinized sections were pretreated by heating them in a microwave oven in 10 mM citrate buffer, pH 6.0, for 15 min. After cooling, the sections were immersed in PBS containing 3 % hydrogen peroxide for 10 min to block endogenous peroxidase activity. Sections were then incubated in a humid chamber (4 h, 4 O ) with a primary antibody against anti-p16
INK4a (CINtec Histology Ò , clone E6H4 Ò dilution, MTM Laboratories, Heidelberg, Germany). After rinsing with PBS, slides were incubated with the secondary antibody followed by the streptavidin-peroxidase complex, both for 30 min at room temperature with a PBS wash between each step (LSAB? system; DakoCytomation Ò , Glostrup, Denmark). The slides were developed with diaminobenzidine-H 2 O 2 (DAB? system; DakoCytomation Ò , Glostrup, Denmark), counterstained with Harry's hematoxylin and mounted. Positive controls consisted of sections of colon cancer; the negative control consisted of replacing the primary antibody with non-immune mouse serum.
Immunostaining analysis
The immunohistochemical staining in the nuclei was assessed using a direct light microscope. A differential count was performed for MSCs and multinucleated giant cells (MGC). Staining was quantified through manual counting of at least 1.000 MSC in 10 different fields at a magnification of 4009. In the same 10 high-power fields, all MGC were counted to a maximum of 1.000 cells. The labeling index (LI) was expressed as the percentage of positive cells with nuclear staining for p16
INK4a in each section (Landber and Roos 1993) .
Statistical analysis
Data were analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). The results were expressed as the mean. To compare the marker LI with respect to clinical forms and the treatment result groups, the non-parametric MannWhitney test was used. Significance was established at a p value B0.05.
The present study was approved by the Ethics Committee of the Hospital Complex of the Federal University of Ceará under protocol 13/08, respecting Resolution 196/96 of the National Council of Health-Ministry of Health/Brazil.
Results
Of the 27 selected cases of CGCL, 24 have enough biological material to perform all reactions. Eleven (45.8 %) were in male patients and 13 (54.2 %) in females, with a median age of 19 years (range from 5 to 50 years). Thirteen (54.2 %) lesions were classified as non-aggressive and 11 (45.8 %) as aggressive CGCL. The age, sex, location, and aggressiveness status of the samples are presented in Table 2 . 
CISH analysis
Normal or low-level CCND1 gene amplification in mononuclear cells (Fig. 2) was found in 14 (58.4 %) lesions and moderate or high-level amplification in 10 (41.6 %) CGCLs (Table 3) . No statistical significance was found (p = 0.697) with respect to association of CCND1 amplification in mononuclear cells and aggressiveness of the CGCL (Table 4) . Also, moderate or high-level CCND1 amplification in multinucleated giant cells was found in 10 (41.6 %) of CGCL, again no association was found with aggressiveness (p = 0.697) ( Table 5 ). Eight of the cases with CCND1 amplification in mononuclear cells also presented amplification in multinucleated giant cells.
Immunostaining analysis
Immunoreactivity for p16 INK4a was detected in 12 cases (50.0 %) in mononuclear cells and only in 5 cases (20.8 %) in multinucleated giant cells ( Fig. 3; Table 3 ). The nonparametric Mann-Whitney test revealed a significantly (p = 0.044) higher level of expression of p16
INK4a in mononuclear cells in non-aggressive CGCLs (Table 6 ). Considering only immunostainig in multinucleated giant cells, 4 positive cases occurred in non-aggressive CGCL, and 1 case in an aggressive lesion.
Correlation between the biomarkers
Analyzing the correlation between CCND1 gene amplification and p16
INK4a immunoreactivity revealed that there was significantly (p = 0.012) higher p16
INK4a expression in mononuclear cells of CGCLs with moderate/high-level CCND1 gene amplification in mononuclear cells (Table 7) . Although only 5 cases showed positive immunoreactivity for p16
INK4a in multinucleated giant cells, 3 of these cases occurred in CGCL with CCND1 gene amplification in multinucleated giant cells (p = 0.615) ( Table 8 ).
Discussion
Some authors have stated that CGCL is an uncommon reactive process that affects the jaw bone and that may be related to trauma, such as dental extraction (Unal et al. 2006) . Aggressive CGCL, with rapid growth and high recurrence rates, are believed to be neoplastic in nature, but the etiopathognesis is still uncertain (Nogueira et al. 2012 ). Analyses of cell cycle regulatory proteins have been used to distinguish neoplastic from reactive conditions and to predict the biological behavior of tumors (Souza et al. 1999) . Few studies regarding cell cycle protein alterations in CGCL have been published (O'Malley et al. 1997; Souza et al. 1999 Souza et al. , 2000 Kauzman et al. 2004 ). The identification of molecular markers characteristic of a lesion and understanding the nature and behavior of a lesion may allow clinicians to better classify and eventually treat such lesions.
In this study, moderate to elevated CCND1 gene amplification in MSC and/or MGC was found in 12/24 cases. Although the authors knows that gene amplification doesn't necessarily, but usually, leads to high protein levels, overexpression of cyclin D1 and CCND1 gene amplification were previously demonstrated by Kauzman et al. (2004) in CGCL, and this overexpression could be implicated in the pathogenesis of CGCL and in the formation of giant cells. Although no statistical significant difference in amplification was found between aggressive and nonaggressive lesions, the amplification of the CCND1 gene could indicate that CGCL may be true neoplastic in nature. Kandel et al. (2006) demonstrated CCND1 gene amplification and cyclin D1 and p21 overexpression in cultured giant cells of GCTs of bones. Kauzman et al. (2003) also found low-level CCND1 gene amplification in 19/31 cases of GCT. In the same study, cyclin D1 and D3 overexpression in multinucleated giant cells and cyclin B1 overexpression and Ki-67 immunoreactivity were detected in (Kauzman et al. 2003) . Expression of Ki-67 and PCNA in the mononuclear cells of CGCLs also indicates that these cells are the proliferative cells in CGCLs (Souza et al. 1999 (Souza et al. , 2000 Liu et al. 2003; Kauzman et al. 2004 ).
Considering p16
INK4a immunoreactivity, this suppressor was detected mainly in mononuclear cells, and a higher level of expression was detected in non-aggressive lesions (p = 0.044). Because p16
INK4a is a negative regulator of cell division that slows down the progression of the cell cycle by inactivating cyclin dependent kinase, the higher INK4a transcription. Alternatively, it could be postulated that, in both aggressive and non-aggressive CGCLs with a neoplastic nature, an epigenetic alteration in mononuclear cells, such as CCND1 amplification, could change the cell cycle. CGCLs with cyclin D1 amplification could have a higher proliferative rate and a more aggressive behavior. However, when there is a negative cell cycle regulator, such as p16
INK4a or another tumor suppressor protein, this lesion could present a slower proliferative rate and thus slower growth. To our knowledge, this is the first report of the study of p16 INK4a expression in CGCLs; other tumor suppressor genes should be investigated to understand the etiopathogenesis of this lesion. Some authors have previously evaluated p53 protein expression in CGCLs, but no immunoreactivity was found (O'Malley et al. 1997; Souza et al. 1999 Souza et al. , 2000 . Supporting the neoplastic nature of CGCL, Carinci et al. (2005) analyzed the genetic profile of two cases of CGCL of the jaws and found some up-regulated and down-regulated genes. In addition, the gene SH3BP2 has been investigated in the pathogenesis of CGCL, Carvalho et al. (2009) described a mutation in the SH3BP2 gene in a case of non-familial CGCL, but Teixeira et al. (2011) investigating 30 cases of CGCL, analyzed all exons known to be involved in cherubism, none of them were mutated.
Although CCND1gene amplification has been observed in CGCLs, no difference was observed between the clinical forms of this lesion. However, the expression of p16 INK4a seems to play a role in aggressiveness of the lesion, those lesions with increased expression of p16
INK4a in MSC may have a more indolent clinical behavior. Also, the findings of the present study corroborate the hypothesis that at least some CGCLs may have a neoplastic origin. These lesions do not fit neatly into the concept of either reactive or neoplastic process; instead, CGCLs exhibit features of both (Regezi and Pogrel 2004) . It could be speculated that CGCLs may develop in two different ways, one being a reactive process and other appears to be a true benign neoplasm, and that CCND1 amplification may contribute to the tumorigenesis of CGCLs. Further studies focused on clinical and molecular analysis, including new studies about cell cycle protein, particularly cyclin D1 protein levels, could help better the understanding of the pathogenesis of CGCL. 
